Surgimate Partners with ImplantBase to Create Unified Surgical Management Platform
Surgimate Partners with ImplantBase to Create Unified Surgical Management Platform Surgimate, a leading provider of surgical coordination software supported by Banneker Partners, has announced its strategic investment in ImplantBase, a top provider of inventory logistics and sales operations software for…
Employer Digital Heart Health Program Linked to Significant Cost Savings, Study Finds
Employer Digital Heart Health Program Linked to Significant Cost Savings, Study Finds A recent study published in the esteemed health economics journal Value in Health reveals significant annual cost savings for employers offering the digital health program Hello Heart as…
Celltrion Receives EC Approval for Avtozma ®, Biosimilar of RoActemra ®
Celltrion Receives EC Approval for Avtozma ®, Biosimilar of RoActemra ® Celltrion has announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a biosimilar to RoActemra® (tocilizumab). This approval encompasses all the indications of its reference…
Tenovi and GenieMD Partner to Expand Remote Care and Boost Medication Adherence
Tenovi and GenieMD Partner to Expand Remote Care and Boost Medication Adherence GenieMD and Tenovi have teamed up to enhance access to healthcare through innovative virtual care models, combining their strengths to offer a more seamless and connected healthcare experience.…
Flosonics Medical Secures $7.5M CAD Venture Debt to Scale Wearable Ultrasound Tech
Flosonics Medical Secures $7.5M CAD Venture Debt to Scale Wearable Ultrasound Tech Flosonics Medical, a Canadian innovator in medical devices, has secured $7.5 million CAD in venture debt financing from RBCx. This funding, along with specialized support, will help accelerate…
QIAGEN Takes Legal Action to Protect IP in QuantiFERON and Latent TB Testing
QIAGEN Takes Legal Action to Protect IP in QuantiFERON and Latent TB Testing QIAGEN NV (NYSE: QGEN; Frankfurt Prime Standard: QIA) has filed a lawsuit against bioMérieux SA (EPA: BIM) for patent infringement, emphasizing its dedication to safeguarding the scientific…
BostonGene to Present AI-Powered Platform at 22nd Annual Japanese Society of Medical Oncology Meeting
BostonGene to Present AI-Powered Platform at 22nd Annual Japanese Society of Medical Oncology Meeting BostonGene, a leader in AI-driven molecular and immune profiling solutions, has announced its participation in the 22nd Annual Meeting of the Japanese Society of Medical Oncology…
Phase III Study: Xolair More Effective with Fewer Side Effects Than Oral Immunotherapy for Food Allergies
Phase III Study: Xolair More Effective with Fewer Side Effects Than Oral Immunotherapy for Food Allergies Genentech, a member of the Roche Group, has announced new positive results from Stage 2 and Stage 3 of the NIH-sponsored Phase III OUtMATCH…
Incyte to Present New Dermatology Data at 2025 AAD Meeting
Incyte to Present New Dermatology Data at 2025 AAD Meeting Incyte (Nasdaq: INCY) today announced that several abstracts showcasing new data from its dermatology portfolio will be presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting, set to…
BeiGene Reports Q4 & Full Year 2024 Financial Results and Update
BeiGene Reports Q4 & Full Year 2024 Financial Results and Update BeiGene, Inc. (NASDAQ: ONC, HKEX: 06160, SSE: 688235), soon to be rebranded as BeOne Medicines Ltd., a global leader in oncology pharmaceuticals, has announced its fourth-quarter and full-year 2024…
BridgeBio Oncology and Helix Acquisition Announce Merger to Create Biotech Company
BridgeBio Oncology and Helix Acquisition Announce Merger to Create Biotech Company BridgeBio Oncology Therapeutics (BBOT), a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics for RAS and PI3Kα-targeted malignancies, and Helix Acquisition Corp. II (Nasdaq: HLXB), a special…
Astria Therapeutics Launches Phase 3 ALPHA-ORBIT Trial of Navenibart for Hereditary Angioedema
Astria Therapeutics Launches Phase 3 ALPHA-ORBIT Trial of Navenibart for Hereditary Angioedema Astria Therapeutics, Inc. (Nasdaq: ATXS), a biopharmaceutical company dedicated to developing transformative therapies for allergic and immune diseases, has announced the launch of the Phase 3 ALPHA-ORBIT clinical…